Cardiff Oncology Inc (CRDF) Stock Price, Quote & News

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 952 7570

Website: www.cardiffoncology.com

Address:

11055 Flintkote Avenue, San Diego, United States

stevelue Jul. 15 at 5:47 PM

$CRDF see prev post....I like the comment from Director Tannenbaum: " You are Joining AT A VERY EXCITING TIME" to new CMO Sidhu....Cheers!

0 · Reply

Tru_Green Jul. 15 at 5:35 PM

$CRDF : New comment posted on LinkedIn by Cardiff Director Tannenbaum for the new CMO Sidhu: "Welcome to the Cardiff team! You are joining at a very exciting time and look forward to your contributions!"

0 · Reply

mankind1 Jul. 15 at 5:06 PM

$CRDF this is an interesting one.

1 · Reply

jerrybe5000 Jul. 15 at 4:13 PM

$CRDF some FUD on X about ECOG imbalance on first thirty patients. Many more ECOG 0 on 30mg arm relative to control (and 20mg in between). Any thoughts on whether that is a significant difference that could “explain” the first set of results? I don’t think it would explain the deepening response in spider plots. The treatment is just an extra pill without any major side effects. Obviously just trying to think of the potential negatives as I have such a big investment here. It is the first time this was brought up if I recall correctly!

4 · Reply

BullRun4 Jul. 15 at 2:55 PM

$CRDF I am adding more today before it breaks resistance at $4.20 and runs up to $5+

0 · Reply

NEWIPO Jul. 15 at 2:44 PM

$CRDF time to buy. Last days to to see thrift store prices here. Short playing with your emotions 😂😂. 4.20 and 4.30 then we fly 💸💸

0 · Reply

NEWIPO Jul. 15 at 2:28 PM

$CRDF rejected. 😂 4.20 is fake wall. 🎆 🎇 🔥 Coming. Hodl and buy the dips

1 · Reply

stevelue Jul. 15 at 2:10 PM

$CRDF Breaking Out on the Monthly...Bullish

1 · Reply

DD_investments Jul. 15 at 2:05 PM

$CRDF the bearish X posts from yesterday were also bearish going into the December data and acknowledged the stronger than expected data afterwards. They’re not wrong about PLK1 inhibitors failing in the past but I don’t believe any of these were combo therapies. If data remains consistent then it’ll be pretty hard for anyone to stay bearish here

2 · Reply

Blakeruss1 Jul. 15 at 1:22 PM

$CRDF kvro knows grand scheme

1 · Reply

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 17, 2025, 4:39 PM EDT - 27 days ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:05 PM EDT - 27 days ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 2, 2025, 4:05 PM EDT - 6 weeks ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 14, 2025, 9:05 AM EDT - 2 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 8, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 2, 2025, 3:35 AM EDT - 2 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Apr 23, 2025, 4:05 PM EDT - 2 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:10 PM EDT - 3 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:05 PM EDT - 3 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Feb 27, 2025, 9:10 PM EST - 4 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 4 months ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 24, 2025, 4:05 PM EST - 5 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 5 months ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 18, 2025, 9:19 AM EST - 5 months ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Dec 14, 2024, 9:00 AM EST - 7 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Dec 12, 2024, 5:38 AM EST - 7 months ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 10, 2024, 5:05 PM EST - 7 months ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 7:20 AM EST - 7 months ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 7 months ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Oct 30, 2024, 4:30 PM EDT - 9 months ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 4, 2024, 1:10 PM EDT - 10 months ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Mar 8, 2024, 7:37 PM EST - 1 year ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 6, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Feb 29, 2024, 8:06 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:07 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:06 PM EST - 1 year ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Jan 17, 2024, 10:30 AM EST - 1 year ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Nov 20, 2023, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 2, 2023, 9:11 PM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Sep 27, 2023, 5:56 AM EDT - 1 year ago

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

COST MLKN PRGS TRUE

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cardiff Oncology to Present at Upcoming Investor Conferences in September

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

Aug 7, 2023, 4:05 PM EDT - 2 years ago

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

May 4, 2023, 4:10 PM EDT - 2 years ago

Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

stevelue Jul. 15 at 5:47 PM

$CRDF see prev post....I like the comment from Director Tannenbaum: " You are Joining AT A VERY EXCITING TIME" to new CMO Sidhu....Cheers!

0 · Reply

Tru_Green Jul. 15 at 5:35 PM

0 · Reply

mankind1 Jul. 15 at 5:06 PM

$CRDF this is an interesting one.

1 · Reply

jerrybe5000 Jul. 15 at 4:13 PM

4 · Reply

BullRun4 Jul. 15 at 2:55 PM

$CRDF I am adding more today before it breaks resistance at $4.20 and runs up to $5+

0 · Reply

NEWIPO Jul. 15 at 2:44 PM

$CRDF time to buy. Last days to to see thrift store prices here. Short playing with your emotions 😂😂. 4.20 and 4.30 then we fly 💸💸

0 · Reply

NEWIPO Jul. 15 at 2:28 PM

$CRDF rejected. 😂 4.20 is fake wall. 🎆 🎇 🔥 Coming. Hodl and buy the dips

1 · Reply

stevelue Jul. 15 at 2:10 PM

$CRDF Breaking Out on the Monthly...Bullish

1 · Reply

DD_investments Jul. 15 at 2:05 PM

2 · Reply

Blakeruss1 Jul. 15 at 1:22 PM

$CRDF kvro knows grand scheme

1 · Reply

look2theblue Jul. 15 at 12:55 PM

$CRDF Today is going to be a great day to SHORT it.

2 · Reply

smolcapcat Jul. 15 at 11:57 AM

$CRDF if you're new here, this could be us but you playin

0 · Reply

frogman2000 Jul. 15 at 11:25 AM

$CRDF just now noticed my Nasdaq alert. Has this always been there? CRDF Alerts × CRDF has a High Technical Rating by Nasdaq Dorsey Wright. Discover why technical analysis matters

0 · Reply

frogman2000 Jul. 15 at 10:25 AM

$CRDF the new comments from clueless accounts shows this is close. No more volume for shorts and the volume that is available is priced very high. These people/organizations are desperate for shares and hence the post like the below. If you have not already covered you better do so soon and stop your bleeding.

2 · Reply

Biobullshitsniffer Jul. 15 at 5:26 AM

$CRDF What if your PT if the data on the 29th is not good vs if great? Thanks.

1 · Reply

NEWIPO Jul. 15 at 1:21 AM

$CRDF to give you an example of how BO works. Let say you bid for a car at a auction, if you win the bid you win not only the car but everything inside. In this case whoever buys us out will also get the drug asset with have on the pipeline as well.

0 · Reply

rag2riches Jul. 14 at 10:24 PM

$CRDF sidhu options SEC 3 filing says it will continue to vest if he "continues to provide services to the Company or an AFFILIATE" According to chatgpt this clause means his options will continue to vest if he continues to work for one of its affilates, such as a subsidary, parent company, or sister company.

2 · Reply

smolcapcat Jul. 14 at 10:12 PM

$CRDF lets get this chart moving

0 · Reply

BullRun4 Jul. 14 at 10:10 PM

$CRDF Just 11 trading days left before shorts give us the big short squeeze 🔥🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

1 · Reply

BullRun4 Jul. 14 at 9:48 PM

$CRDF 🔥🔥🔥🔥 Shorts 🔥🔥🔥🔥

0 · Reply

oligo Jul. 14 at 9:22 PM

$CRDF No Mind

1 · Reply

oligo Jul. 14 at 9:15 PM

$CRDF https://youtu.be/4wJBg38Kco0?si=W3N_pivh_Y_JG8Vj

1 · Reply

Market Cap	270.76M
Revenue (ttm)	680,000.00
Net Income (ttm)	-45.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,680.88%
Debt to Equity Ratio	0.00

Volume	550,982
Avg Vol	1,143,030
Day's Range	N/A - N/A
Shares Out	66.53M
Stochastic %K	91%
Beta	1.52
Analysts	Strong Sell
Price Target	$12.10